Graybug Vision, Inc. (GRAY)
| Market Cap | 75.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.42M |
| Shares Out | 21.28M |
| EPS (ttm) | -2.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,398 |
| Open | 3.74 |
| Previous Close | 3.73 |
| Day's Range | 3.65 - 3.75 |
| 52-Week Range | 3.43 - 37.88 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 4.75 (+29.4%) |
| Est. Earnings Date | Nov 10, 2021 |
About GRAY
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopath...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Graybug Vision stock is "Strong Buy." The 12-month stock price forecast is 4.75, which is an increase of 29.43% from the latest price.
News
Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference
BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases...
Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Dev...
REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...
Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...
Is the Options Market Predicting a Spike in Graybug Vision (GRAY) Stock?
Investors need to pay close attention to Graybug Vision (GRAY) stock based on the movements in the options market lately.
Graybug Vision Shorts Got A Serious Squeeze: What's Next?
Graybug Vision Inc (NASDAQ: GRAY) has not released any news since it printed its first-quarter 2021 earnings results May 12, but that didn't stop the stock from closing up 22% on Thursday and soaring fu...
Graybug Vision Reports Full Data Analysis After One Year Treatment Of GB-102 In Wet AMD
Graybug Vision Inc (NASDAQ: GRAY) has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration (wet A...
Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
3 Net Current Asset Value Stock Picks
There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe they can gain from these kinds of investments after the market has reappraised the...
Why Is Graybug Vision Stock Plunging Today?
Graybug Vision Inc (NASDAQ: GRAY) shares are dropping after preliminary data from Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD). Investors are reacting to the mea...
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...
Graybug Vision to Participate in SVB Leerink Global Healthcare Conference
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company's Executive Team
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...
Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second ...
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...
Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference
REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporat...
REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...
Graybug Vision's stock open up 19%, then pares some gains
Graybug Vision Inc.'s stock started its public life with a rally, as it opened 18.8% above its initial public offering price. The first trade was at $19.00 at 12:15 p.m.
Graybug Appoints Three New Members to its Board of Directors
REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic...
Graybug Vision prices upsized IPO at midpoint of expected range, raises $90 million
Graybug Vision Inc. GRAY, +2.59% said early Friday that its upsized initial public offering priced at $16 a share, in the middle of the expected range of $15 to $17 a share.
Graybug Vision Announces Pricing of Upsized Initial Public Offering
REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic...
Graybug Vision Readies $75 Million IPO Effort
Graybug Vision has filed to raise $75 million from the sale of its common stock in a U.S. IPO.